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INCREASING COMMUNICATION THROUGH IMPROVED NURSING
EDUCATION
Increasing communication through improved nursing education: The histories, policies
and manufacturing process of vaccines
From birth to age 18, a child can receive up to 42 doses of scheduled vaccines, not
including annual influenza vaccinations. Vaccines are an important part of a child's life,
aiming to prevent the child from contracting serious and potentially deadly diseases that
in the past have killed several million children collectively throughout the world. While
many vaccines today contain antigens for diseases that have been considered eradicated,
it is important to continue vaccination to prevent wild type versions of eradicated
diseases from working its way back into the population. Should an event like this happen,
immunocompromised and young children could contract diseases like polio and
diphtheria, serious diseases that killed thousands of children over the last 100 years.
This paper will outline the history of many vaccines that are recommended by the
World Health Organization (WHO), the severity of illness those diseases cause, the
vaccine manufacturing process, and vaccine policies. These topics will highlight the
rationale of why children should continue to be vaccinated against said diseases.
The nurse's role in enhancing communication between parents and providers is
one of the most important aspects of the paper, as alarmingly increasing numbers of
parents have decided to withhold from vaccinating their children. It is through providers'
increased communication that successful vaccination rates will improve, thereby
decreasing incidences of preventable disease and death.
History of Disease and Vaccine Production
Parents today do not seem to recognize the severity of the diseases modern
children are vaccinated against, as many state they do not believe their children need
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vaccines for the diseases the CDC recommends. Parents believe this due to the sparse
incidences of preventable disease that remain in the United States (London et al. (2017).
The history of how vaccines became as important for human health as they are
today began with the smallpox vaccine. Research on the smallpox vaccine opened the
door for many other vaccines to be produced and perfected.
Smallpox
Smallpox is a progressive disease with several stages, each with different
symptoms. During the initial stage, an individual may be contagious with a high fever,
head and body aches, and vomiting. In the early rash stage, the individual is most
contagious with a rash that manifest as small red spots on the tongue and in the mouth.
The spots break open and turn into sores that ooze the virus into the mouth and throat. A
skin rash begins on the face and spreads down to the arms and legs. After 10-14 days, the
pustular rash scabs over and fall off. After approximately four weeks, all scabs will have
fallen off and the individual is no longer contagious (Center for Disease Control and
Prevention, 20 16c).
History of disease.
Smallpox can be traced back to approximately 10,000 BC in northeastern Africa
(Riedel, 2005). Mummies from I 570-1085 BC were the first to be noted with smallpox
pustules on their faces. In the 18th century, approximately 400,000 Europeans died
annually from the disease (Riedel, 2005). Those who survived were left with significant
scarrmg.
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History of vaccination.
One of the first recorded incidences of vaccination occurred in China around 9001000 A.D, when physicians noted that people who were exposed to the scabs of those
with smallpox developed either a milder version of the disease or no symptoms at all.
Physicians crushed the scabs into a powder and directed those at risk to inhale the powder
through the nose. For hundreds of years after, thousands of people were protected from
smallpox with this method in Asia, Africa, and the Middle East {Feemster, 2018, p. 17).
The first record of inoculation in the United States was in 172 1 during the Boston
smallpox epidemic. Cotton Mather was first introduced to inoculation by slaves from
Africa who were inoculated in their home country. While Mather was adamant in treating
the ill, there were not any physicians who gave their support. Dr. Zabdiel Boylston
agreed to inoculate as many patients as he could with the help of Mather. Dr. Boylston
introduced fluid from an infected individual's pustule to a healthy individual through a
small cut made in the skin. The individual would still develop smallpox, but a generally
milder case. Those who were inoculated this way were also protected from additional
smal1pox infections through antibody protection. At the end of the epidemic, Boylston
had inoculated approximately 248 patients (Feemster, 20 18, p. 18).
Through additional smallpox epidemics through the years, more and more people
began to believe that the practice of inoculation was beneficial. Since smallpox was
incredibly contagious, those who received the inoculation were quarantined afterwards to
prevent the spread ofinfection. This was difficult for healthy individuals who felt that it
was unnecessary to make themselves willfully ill for the sake of not contracting the full
blown smallpox disease. As successful inoculations began to rise, the medical community
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slowly embraced the practice, though it was still considered illegal in many colonies for
years to come (Feemster, 2018).
In 1796, Dr. Edward Jenner treated a milkmaid who stated she had never
contracted smallpox because she had been exposed to cowpox. Cowpox was a rarer and
less severe disease that mostly infected farmworkers through contact with cow udders.
Jenner extracted pus from a milkmaid's cowpox lesion and injected an eight-year-old
boy, James, with it. Six weeks later he injected James with smallpox. The boy never
developed any symptoms of smallpox at that time, nor did he contract any subsequent
smallpox infections {Stem & Markel, 2005, p. 612). By this experiment, Jenner was able
to prove that cowpox protected individuals from smallpox infections. Five years later, in
1801, nearly 100,00 people had been vaccinated with the first cowpox-based vaccine
throughout Europe (Feemster, 2018, p. 20).
By 1801, smallpox was still ravaging its way through America, though curiously,
American cows did not suffer from cowpox. This made it difficult to create a vaccine like
Jenner's. Thomas Jefferson, the American president at the time, was the first to establish
the import of cowpox fluid to use in vaccines against smallpox from Europe. The vaccine
was pushed in more urban areas, where smallpox outbreaks were more likely due to
living in closer quarters (Stem & Markel, 2005).
Eradication.

With increased mass vaccination efforts, the last case of naturally acquired
smallpox occurred in Somalia in 1977 (Center for Disease Control and Prevention,
2016b). The patient made a full recovery after a period of isolation. On May 81\ 1980,
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smallpox was declared eradicated throughout the world (Center for Disease Control and
Prevention, 2016b). Diseases that have been eradicated or are approaching near
eradication by the WHO will be mentioned throughout the paper, though not all diseases
listed have published eradicated efforts.
Polio

Poliovirus is an enterovirus causing the poliomyelitis disease. Poliomyelitis is an
acute paralytic disease stemming from lower motor neuron damage that results in
unilateral or bilateral lower extremity weakness (Baicus, 2012). The upper extremities,
throat, chest and facial muscles may also be affected.
History of disease.

Poliomyelitis has been traced back to ancient times of Egyptians, approximately
1580-1350 BCE, where steles showed an adult with a smaller, flaccid looking leg and a
crutch; similar to what victims of poliomyelitis looked like in the 1900s (Nathanson &
Kew, 2010). While poliomyelitis was observed in European countries prior to the United
States, the first documented cases of polio in the United States were seen in 1894 in
Rutland County, Vermont by Dr. Charles Caverly (The College of Physicians of
Philadelphia, 20 18b). There were 18 deaths and 132 cases of permanent paralysis. While
Caverly was one of the first physicians to recognize that polio could occur with or
without permanent paralysis, he did not believe that the disease was contagious and could
be spread. It would not be discovered that poliomyelitis was indeed contagious until I 905
by Swedish physician Ivar Wickman (The College of Physicians of Philadelphia, 2018b).
Polio was found to be passed from person to person via pharyngeal secretions and
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contaminated feces, as polio entered through the oral route and traveled through the
digestive tract (Nathanson & Kew, 2010).
In 1916, the United States faced its first of many summertime polio epidemics
that claimed the lives of 2,000 people in New York City alone, and approximately 6,000
total across the country, leaving thousands more paralyzed in its wake (The College of
Physicians of Philadelphia, 2018b). In 1929, the use of the iron lung, an artificial
respirator, was used for patients with paralytic polio who could no longer breathe on their
own due to the diaphragm and intercostal muscles becoming paralyzed (The College of
Physicians of Philadelphia, 2018b).

Vaccine history.
The first polio vaccine trials began in 1935, four years after Australian researchers
Frank Burney and Jean McNamara found that there was more than one type of poliovirus.
Maurice Brodie and John Kollmer both set to work producing the world's first polio
vaccines. However, there was no extensive testing prior to vaccinating thousands of
subjects. Brodie's vaccine was made with a killed virus that did not leave the subject with
a sufficient level of antibodies to fight off the virus and produced severe allergic reactions
in some recipients. Kollmer's vaccine was made with the live polio virus was not
attenuated correctly, producing polio in some of the recipients (Baicus, 2012). Because
there were no regulations on human experimentation, many test subjects died of either
poliomyelitis, severe allergic reactions, were left paralyzed, or were made ill (The
College of Physicians of Philadelphia, 2018b).
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In 1948, Dr. Hilary Koprowski, a researcher from Lederle Laboratories, ingested
his Type II poliovirus vaccine after testing it successfully on chimpanzees. He did not
suffer any ill effects. This discovery came one year before David Bodian, MD, PhD and
Isabel Morgan, PhD published their work that identified three types of polioviruses. This
research was monumental in the development of vaccines for poliovirus, as the vaccine
would need to prove immunity to all three types of the virus (The College of Physicians
of Philadelphia, 2018b). Dr. Koprowski began his human trials of his vaccine in 1950,
beginning with 20 disabled children at a New York State facility. It was proven a success
as not one child developed polio, and all developed the Type II poliovirus antibodies
{The College of Physicians of Philadelphia, 20 18b).
Another surge of the polio epidemic shook the United States in 1952, infecting
approximately 57,628 people and paralyzing more than 21,000 of them. Jonas Salk and
his team of researchers began their first human subject testing in 1952 using their killed
virus vaccine (inactivated poliovirus (IPV)). The subjects were institutionalized children
that were physically or mentally disabled. It was found that the subjects developed
antibodies to the type of poliovirus they were vaccinated with, which gave way to larger
scale trials. The Vaccine Advisory Committee approved a large-scale human trial that
included a double-blind study of over 1.3 million American children in 1954 (The
College of Physicians of Philadelphia, 20 18b). Only the researchers knew which child
had been vaccinated with either the polio vaccine or placebo fluid. It was found a year
later that Salk's poliovirus vaccine proved to be 80-90% effective, and the United States
government licensed the vaccine the same day (The College of Physicians of
Philadelphia, 2018b).
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A few months after the vaccine was licensed, reports from local health authorities
began to show new cases of paralytic polio in newly vaccinated children. Paralysis
appeared to begin in the vaccinated arm compared to the more common lower extremities
(The College of Physicians of Philadelphia, 2018b). An investigation traced the issue
back to Cutter Laboratories based in California, which gave way to public health officials
making drastic changes to the production of the poliovirus vaccine and later all other
vaccines. Changes included testing larger samples of each vaccine lot, lengthen the
treatment time with formaldehyde, and use special filters that could filter accumulations
of the virus that would be resistant to the chemical inactivation of formaldehyde (The
College of Physicians of Philadelphia, 2018b).
By 1957, Koprowski had begun trials of a new oral poliovirus (OPV) vaccine that
only provided immunity against Type I poliovirus in the Democratic Republic of Congo.
While the vaccine did not provide protection against all three types of poliovirus, Type I
was most widely found in the Congo (The College of Physicians of Philadelphia, 2018b).
Albert Sabin worked with Soviet health officials to produce an OPV that included
all three polioviruses. Sabin's live vaccine was cheaper to produce than Salle's IPV
vaccine. It also was proved to have many advantages over the IPV. The OPV produced
an immune response faster than the IPV and traveled through the entire digestive system
unlike the IPV. The OPV was given on a sugar cube and was preferred by children
compared to a vaccine. One issue that was found with the OPV was that the virus could
revert to virulent forms, whereas the IPV could not (The College of Physicians of
Philadelphia, 2018b). With these advantages in mind, the Soviet Union vaccinated over
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10 million Soviet children using the OPV vaccine and did not include a control group
(The College of Physicians ofPhiladelphia, 2018b).
In 1960, the United States' Surgeon General recommended that Sabin's OPV
vaccine be licensed for use in the US. At first, the vaccine only provided protection
against Type 1 poliovirus, but all three types were included in the vaccine by 1963 (The
College of Physicians of Philadelphia, 2018b).
Salk's IPV vaccine was slowly phased out in 1968, as the OPV vaccine was
greatly preferred by the public and the American government. It would be used again in
1997 when authorities found that an average of 8-10 polio cases per year were caused by
the OPV vaccine (The College of Physicians of Philadelphia, 2018b). By 2000, the OPV
vaccine would no longer be used in the United States, completely switching to a new and
improved version of Salk's IPV vaccine. However, the rest of the world, specifically
underdeveloped countries, would continue to use the OPV vaccine (The College of
Physicians of Philadelphia, 2018b).
The World Health Organization (WHO) set a goal in 1985 for polio to be
completely eradicated from the Americas by 1990, however, polio was not declared
eradicated from the Americas until 1994. In 2000, it was found that there had been a
reduction of wild polio cases by 99%, a decrease from 350,000 cases in 1988 to only 719
worldwide in 2000 (The College of Physicians of Philadelphia, 2018b). Wild polio cases
were considered polio diagnoses that did not stem from recent polio vaccinations or
contact with a recently vaccinated individual (The College of Physicians of Philadelphia,
2018b).
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In April of 2016, the elimination of Type II poliovirus vaccines began to stop
vaccine-derived Type II polio in high risk countries. Approximately 150 countries still
using the OPV vaccine were directed to switch from the three-strain OPV to the two
strain vaccine. Because there has not been a case of wild Type II poliovirus since 1999,
the WHO hopes that Type II poliovirus should eventually die out, leaving only Types I
and III to be eliminated (The College of Physicians of Philadelphia, 2018b).
Today, polio has still not been declared eliminated worldwide. The number of
wild poliovirus cases are still decreasing, most recently reported as 22 cases worldwide in
2017 compared to 37 reported cases in 2016. All cases in 2017 were in Afghanistan,
Nigeria, and Pakistan, where political unrest appears to make continuing to vaccinate the
population difficult. The WHO's focus is to fully eradicate poliovirus, as even with
today's medical and scientific advancements, there is no cure for polio. Pain relievers,
ventilators, and physical therapy are the only available treatments for individuals affected
by the disease (The College of Physicians of Philadelphia, 2018b).
Measles, Mumps, and Rubella (MMR)
Measles.

Measles is an infectious viral disease that induces systemic infection in an
individual via respiratory secretions. The incubation period lasts 10-12 days, followed by
a prodromal phase lasting 2-4 days. During this time, the individual will experience high
fever, cough, and runny nose. After the prodromal phase, Kolpik spots form on the buccal
mucosa. The spots are characteristic to the disease and normally can be used for a
differential diagnosis. A fully body measles rash appears shortly after, lasting 5-6 days. It
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begins on the head and moves laterally and inferiorly to the hands and feet and fades in
order of appearance several days later (Hamborsky, Kroger, & Wolfe, 2015).
Complications are more likely in children younger than five and adults older than 20 and
include anorexia, diarrhea, otitis media, pneumonia, and acute encephalitis. Deaths that
occur from the disease are usually complicated with secondary disease, such as
pneumonia (Hamborsky, Kroger, & Wolfe, 2015).
History of disease.
In 1676, English physician Thomas Sydenham published his paper successfully
distinguishing smallpox from measles, but it wasn't until 1757 that measles was
identified to be an infectious virus (Oldstone, 20 l 0).
During the American Civil War, particularly in 1861, there were 21,676 cases of
measles with 551 deaths due to respiratory or cerebral complications (Oldstone, 2010).
People all over the world continued to contract measles, some dying from secondary
complications. There were not any advances in finding a cure nor a vaccine combination
to stop the spread of infection until 1916, when the measles-specific antibodies were
identified. Patients that had been previously infected by measles had a protective
antibody in their blood. Drs Charles Nicolle and Ernest Conseil believed that the serum
from measles patients' blood could be used to provide immunity to those who had not yet
contracted the disease (Oldstone, 2010). Meanwhile, the disease killed over 12,000
Americans in the same year. The highly infectious disease continued to spread, leading to
a massive outbreak in southern Greenland that affected 99.9% of the population, many of
them dying (Oldstone, 2010).
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Vaccine history.
Dr. Thomas Peebles was the first to isolate the measles virus in 1954, doing so
from the blood of a 13-year-old boy who had been infected with measles. The isolated
virus would then be used to create the first of a series of vaccines. Dr. Peebles employed
Dr. Sam Katz, who in 1958 tested the first measles vaccine on mentally and physically
disabled children. All children developed the antibodies, but most also developed a rash
from the vaccine. For the vaccine to be considered effective, the virus would need to be
weakened more (Oldstone, 20 10).
The first successful measles vaccine was created by John Enders and was licensed
in 1963. Over the next 12 years, 19 million vaccines would be administered, however one
downfall of the vaccine was that an injection of gamma globulin would also need to be
administered to reduce complications and adverse effects (Oldstone, 2010). Merck
pharmaceutical company used Enders' vaccine to create a more attenuated version of the
vaccine. To weaken the virus further, it was passed through chick embryo cells 40 times.
By weakening the vaccine, it eliminated the need of gamma globulin injections and
showed less adverse effects. Since its licensure in 1968, it has been the only measles
vaccine used in the U.S (Oldstone, 2010).
Measles was declared eliminated from the United States in 2000, however in
2014, there was an outbreak of 111 cases of measles at Disneyland in Anaheim,
California. Most of the infected individuals were children who had not reached the
minimum age threshold to be vaccinated for measles, or individuals who were never
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vaccinated for the disease. Infected individuals spread the disease to five different states
and Mexico by the end of 2015 (Broniatowski, Hilyard, & Dredze, 2016).
Mumps.
Mumps is an acute viral illness caused by the paramyxovirus Rubulavirus. The
virus, like measles, is spread through respiratory droplets or by touching surfaces
previously contaminated with respiratory droplets from an infected individual. During the
prodromal phase which lasts for approximately two days, symptoms usually consist of
headache, malaise, muscle pain, and fever (World Health Organization, 2007). This
period is when an individual is most contagious, as well as for approximately nine days
after the onset of swelling of the parotid glands, the most characteristic symptom of
mumps. Other complications may include asymptomatic pleocytosis, found in 50-60% of
patients, and symptomatic meningitis, found in approximately 15% of patients (World
Health Organization, 2007).
While mumps is not considered a deadly disease, secondary complications may
occur. Paralysis, seizures, cranial nerve palsies, aqueductal stenosis, hydrocephalus, and
deafness are the most reported serious secondary complications. Approximately 25% of
women who contract mumps during the first 12 weeks of pregnancy experience
spontaneous abortion (Center for Disease Control and Prevention, 2015a).
History of disease.
Mumps has been found throughout history as early as 50, century BC. Hippocrates
described the disease as swelling near the ears, with some males having testicular
swelling of one or both testicles (Choi, 2010). Johnson and Goodpasture studied the
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etiology of mumps by showing that the virus could be transmitted from infected humans
to monkeys in 1934 (Center for Disease Control and Prevention, 20 15a). The virus was
not isolated and cultured until 1 945, and the first vaccine for mumps, a killed virus
vaccine, was licensed and used throughout the United States from 1950 to 1978. It
induced short term immunity but showed low efficacy (World Health Organization,
2007).
Vaccine history.
Maurice Hilleman created the first live attenuated mumps vaccine in 1967 by
isolating the virus from the saliva of his five-year-old daughter, who had been infected
with mumps. The vaccine was named after his daughter, Jeryl-Lynn. Merck bought the
vaccine from Hilleman in 1967, renaming it Mumpsvax. While other countries have
developed their own vaccines against mumps, the United States has continued to use
Hilleman's vaccine since it was licensed. It was combined with the measles and rubella
vaccine in 1971 to create today's MMR vaccine (World Health Organization, 2007).
Rubella.
Rubella is considered a rather mild disease, caused by a togavirus virus, named
Rubivirus (Center for Disease Control and Prevention, 20 15b). Symptoms of acquired
rubella include with low grade fever, headache, conjunctivitis, muscle aches,
lymphadenopathy, cough, and rhinorrhea. Some patients develop a mild red rash that
begins on the face and moves inferiorly. It usually dissipates in the same sequences three
to four days after onset. Approximately 25-50% of individuals with rubella will not show
any symptoms of disease (Center for Disease Control and Prevention, 20 16a). There is no
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cure or treatment, other than acetaminophen or NSAIDs to reduce fever and muscle
aches.
History of disease.
First previously described as a variant of measles, rubella was not considered a
separate entity until 1814 by George Maton in Germany, who named it the German
measles. In 1914, Alfred Fabian Hess described Rubella to be a virus after working with
the infection on monkeys (Center for Disease Control and Prevention, 20 15b). Hess'
beliefs were confirmed in 1938 when Hiro and Tosaka were able to replicate the virus by
using clean and filtered nasal washings from children to induce infection in healthy
schoolchildren who had not been previously exposed (Center for Disease Control and
Prevention, 20 15b). In 1966, rubella became a nationally recognized infectious disease,
with 57,686 cases reported in the United States in 1969 alone (Center for Disease Control
and Prevention, 20 15b).
Vaccine history.
Three rubella vaccines were licensed in 1969, RA 27/3, or Meruvax, attenuated
through duck embryo, Rubelogoen, attenuated through dog kidney, and Cendevax,
attenuated through rabbit kidney. Rubelogen was removed from the market shortly after
licensing after reports of severe joint pain following vaccination (Plotkin, 2005). In 1971,
the rubella vaccine was added to the mumps and measles vaccines, effectively created the
MMR combination vaccine. In 1979, the Meruvax and Cendevax vaccines used in the
MMR were discontinued to make way for the Meruvax II vaccine to be included in the
MMR vaccine (Center for Disease Control and Prevention, 20 15b).
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Meruvax II is a live attenuated virus vaccine first isolated in 1965 from a rubella
infected fetus that was spontaneously aborted (Center for Disease Control and
Prevention, 20 15b). The virus was passed through the fetus's tissue 25-30 times using
human diploid fibroblasts. Meruvax was replaced by the Meruvax II vaccine due to its
high efficacy percentage, over 95%, inducing lifelong immunity with only one dose
(Center for Disease Control and Prevention, 20 I Sb).
Combination MMR vaccine history.

The combination MMR vaccine was developed in 1971 by Merck and was
incredibly effective. Further testing that began several years prior to licensure showed
that the adverse effects of the MMR vaccine did not outweigh the adverse effects of any
single measles, mumps, or rubella vaccine (Center for Disease Control and Prevention,
20 15b).
In 1998, Andrew Wakefield published a popular article in the Lancet, claiming
that the MMR vaccine had impacted the digestive systems of children, inducing autism
(Wakefield, 1998). Vaccination rates subsequently plummeted, increasing outbreaks of
measles around the world. Among controversy, the paper was retracted by the Lancet,
after it was found that there was no link between the vaccine and autism. Wakefield later
was barred from practicing medicine in Britain. While many studies have not been able to
find a link between the MMR vaccine and autism like Wakefield claimed to do, many
parents are still convinced that the MMR vaccine was responsible for their child's
development of autism.
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Diphtheria, Tetanus, and Pertussis (DTaP or TDaP)
Diphtheria.

Diphtheria is a bacterial infection of Corynebacteri um di phtheriae that is spread
from individual to individual through respiratory droplets and secretions that are inhaled.
The bacteria infect the upper airways and throat and damages other organs by producing
a toxin that could cause myocarditis and peripheral neuropathy. The bacteria colonize in
the throat before excreting a toxin that destroys the surrounding cells, forming a thick
gray membrane over the pharynx that can obstruct the airway (The College of Physicians
of Philadelphia, 20 18a).
Presently, treatment for diphtheria is aggressive. Physicians inject the infected
with the diphtheria antitoxin to neutralize it. Penicillins and erythromycin are used to
combat the bacteria (Mayo Clinic, 2018). In most cases, the patient needs to be
hospitalized for observation and to prevent the patient from spreading the highly
contagious disease to others (Mayo Clinic, 2018)..
History of disease.
The first record of diphtheria-like symptoms appeared in 1613 during a Spanish
epidemic. It was known as the year of strangulations, "El Aiio de los Garotillos" (The
College of Physicians of Philadelphia, 20 1 8a). Halfway through the fifteenth century,
diphtheria epidemics swept their way through New England, killing entire families of
children. In 1735, diphtheria was known as the "plague of children", as the disease
targeted mostly children under 10 years of age. It is believed that anywhere between 32-
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40% of the children under 1 0 were killed by the disease in New England (The College of
Physicians of Philadelphia, 20 18a).
In 1836, French physician Pierre Bretonneau gave diphtheria its name, diphta-ite
He also was the first to successfully use a tracheostomy to remove throat secretions and
allow patients to breathe with more ease. This was the only effective treatment for the
disease at the time, and only approximately 25% of patients survived the tracheostomy.
Tracheostomies continued to be used until 1885, when American physicians Joseph P.
O'Dwyer introduced intubation. O'Dwyer created the tools and methods needed for the
procedure, which quickly replaced the use of the tracheostomy, as it was less invasive
with higher patient outcomes (The College of Physicians of Philadelphia, 2018a).
Vaccine history.
In 1890, Shibasaburo Kitasato and Emil von Behring isolated the S diphtha"iae
anti-toxin in guinea pigs. The scientists injected heat-treated bacteria into guinea pigs and
found that animals' blood contained a substance, antitoxin, that prevented the guinea pigs
from being reinfected when injected with the bacteria again (The College of Physicians
of Philadelphia, 2018a). Kitasato and von Behring also found that by injecting an infected
animal with the blood serum from an immunized animal, it would cure the animal of
diphtheria. This practice was named serum therapy. By 1 894, the antitoxin had made its
way to production in the United States. G.J Hermann, MD and Charles Reynolds, MD
used antitoxin to treat the youngest of four children who had all contracted diphtheria.
The treated youngest child and another untreated child survived, while the other two
children did not (The College of Physicians of Philadelphia, 20 18a). A year later, the
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antitoxin began to be tested and produced, first by Mulford Company of Philadelphia,
then the New York City Health Department (The College of Physicians of Philadelphia,
20 18a).
Emil von Behring published a study in 1907 that showed that by mixing the
diphtheria toxin and the antitoxin in a precise way, it produced lasting immunity in
humans. The balance between the toxin and antitoxin needed to be just right to elicit an
immune response yet prevent the toxin from causing disease (The College of Physicians
of Philadelphia, 20 18a).
The Schick test was an important development in the diagnosis of diphtheria. Bela
Schick created the test in 1913 by injecting a small amount of diphtheria toxin under the
skin that would either produce reddening and swelling at the inject site, or no change. If
there was no change after the injection, this was a negative reaction-a sign that the
patient had been previously exposed to the diphtheria toxiri and was immune to the
bacteria (The College of Physicians of Philadelphia, 20 18a). The Schick test was used
throughout Europe before Schick immigrated to New York City and implemented the use
of his test throughout the city (The College of Physicians of Philadelphia, 20 18a).
In 1926, Alexander Thomas Glenny added aluminum salts to the vaccine to
increase the effectiveness, and therefore immunity of the diphtheria vaccine (The College
of Physicians of Philadelphia, 20 18a). The salts increased the level of antibody response,
increasing the length of immunity. Today, substances like aluminum salts are called
adjuvants, and they are still used in many modem vaccines.
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In the 1970s, it was estimated that there were approximately one million cases of
diphtheria that killed 50,000-60,000 people each year in undeveloped countries (World
Health Organization, 20 17).
Tetanus.

Tetanus is serious disease caused by an exotoxin released by Clostridiumtaani . It
is often fatal if left untreated or vaccinated for. The bacteria are found in an individual's
environment and are not contagious. C. taani can be found in soil and the intestines and
feces of many animals. There have also been cases of C. tetani found in contaminated
heroin (The College of Physicians of Philadelphia, 20 18e). Since tetanus enters the body
through a wound on the skin, wound care and management are most important in at risk
individuals. Use of the tetanus immune globulin (TIG) is important to remove tetanus that
has not traveled to nerve endings (Center for Disease Control and Prevention, 2015e).
Once the exotoxin binds to the nervous system, TIG will not remove it. There is no cure
for tetanus, only medication and antibiotics to relieve symptoms, along with wound care
can help manage the disease until complete recovery (Center for Disease Control and
Prevention, 20 15c).
There are three different forms of tetanus. The most common, generalized tetanus,
presents with a descending pattern starting with the jaw {lockjaw), neck stiffness,
difficulty swallowing, and stiffened abdominal muscles. Other presenting symptoms may
include pyrexia, diaphoresis, hypertension, and tachycardia (Center for Disease Control
and Prevention, 2015c). Complete recovery of tetanus may take months. In some cases,
intubation and use of a ventilator are needed when the muscles needed for respiration are
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affected. If contractions of the muscles are strong enough, bone fractures may also occur
(The College of Physicians of Philadelphia, 2018e). Local tetanus is uncommon, where
patients have sustained local muscle contraction where the bacteria entered the body. The
contractions can last for several weeks and may precede the onset of a milder form of
generalized tetanus (The College of Physicians of Philadelphia, 2018e). Cephalic tetanus
is the rarest and are usually contracted by C. tetani entering the ear canal, causing otitis
media, or wounds to the head. There is usually involvement of the cranial nerves (The
College of Physicians of Philadelphia, 20 18e).
History of disease.
While there are records of tetanus-like symptoms from 500 BCE, it was not until
1884 that the first tetanus infection was produced in animals. Antonio Carle and Giorgio
Rattone discovered the etiology of tetanus by taking pus from a deceased human with
tetanus and injecting it into animals (Center for Disease Control and Prevention, 2015c).
Arthur Nicolaier, a German-Jewish internist, produced tetanus in animals by injecting
them with soil the same year (Center for Disease Control and Prevention, 20 15c).
In 1889 Baron Kitasato Shibasaburo, a Japanese bacteriologist, isolated C. tetani
from a human and injected it into animals to produce disease. He also reported that
antibodies could neutralize the spread of the exotoxin {Center for Disease Control and
Prevention, 20 15c).
Vaccine history.
French bacteriologist and veterinarian, Edmond Nocard, published research of a
tetanus antitoxin that induced immunity in humans in 1897 (Center for Disease Control
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and Prevention, 20 15c). He stated the antitoxin could be used for prophylaxis and
treatment of tetanus.
Gaston Ramon found that by using formaldehyde to inactivate the tetanus toxoid,
it would induce immunity in its receiver without inducing infection. This finding led to
the development of the first tetanus toxoid vaccine in 1924 by P. Descombey (Center for
Disease Control and Prevention, 20 15c).
The single vaccine for tetanus is still available and is recommended that
individuals receive a booster shot every ten years, or six vaccines total to ensure that the
body remains immune to the exotoxin, especially because there is no way to test for
tetanus. It is only diagnosed by clinical symptoms (Center for Disease Control and
Prevention, 2015c).
Pertussis.

Pertussis is an incredibly contagious disease that is spread through respiratory
secretions of an infected individual. The disease causes uncontrollable violent coughing
that impedes breathing and can cause apneic episodes. Vomiting after paroxysms are also
common. The disease mostly affects children under the age of one, and approximately
50% of babies who contract pertussis need to be hospitalized for treatment (Center for
Disease Control and Prevention, 2017).
In patients with pertussis, early detection and treatment is important. Currently,
use of antimicrobials such as azithromycin, clarithromycin, and erythromycin are
common. Trimethoprim-sulfamethoxazole may also be used. The CDC recommends that
anyone who may have been exposed to pertussis be treated with a prophylactic regime,
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especially those who are high risk or are in contact with high risk patients, such as
children under the age of one (Center for Disease Control and Prevention, 20 17).
History of disease.
One of the first epidemics of pertussis, or whooping cough, was described in
Paris, France in 1578 by Guillaume De Baillou, who believed the name came from the
distinctive cough that individuals with the disease had (The College of Physicians of
Philadelphia, 2018d). For the next two hundred years, pertussis made its way through the
U.S population, but there were no advances until 1906 when Bordet and Gengou isolated
the bacterium, Bordetella pertussis (Cherry, 1996). In 1912, Bordet and Gengou
attempted and failed to create a pertussis vaccine from killed whole cell B. pertussis (The
College of Physicians of Philadelphia, 20 18d).
Vaccine history.
In 1939, American bacteriologist Pearl Kendrick and Grace Elderding publishing
their findings of an effective pertussis vaccine they had created and tested. The vaccine
was used until it was combined with diphtheria and tetanus (DTP) in 1948. The DTP was
discontinued in the mid-1990s due to concerns of adverse reactions. The killed whole cell
pertussis vaccine was replaced with an acellular vaccine, creating the DTaP vaccine that
is used presently (The College of Physicians of Philadelphia, 20 18d).
Combination diphtheria, tetanus, and pertussis vaccine.
The diphtheria, tetanus, and pertussis vaccines were combined in 1948 to create
the DTP vaccine. The World Health Organization (WHO) recommended the combination
diphtheria, tetanus, and pertussis vaccine in 1974 for its Expanded Program on
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Immunization (EPI) in developing countries. While these diseases had nearly disappeared
in developed countries in Europe and the United States, polio, diphtheria, pertussis, and
tetanus continued to ravage developing countries, killing thousands of children. It is
estimated that fewer than 5% of all children throughout the world had been vaccinated by
their first birthday (The College of Physicians of Philadelphia, 201 8a). The whole-cell
pertussis antigen was replaced with the acellular pertussis antigen, renaming in the
combination vaccine DTaP in the early 1 990s (Skibinski, Baudner, Singh, & O'Hagan,
201 1).
Several categories of vaccines were produced throughout the last century to
provide the best protection from a disease while avoiding many secondary side effects
due to inadequately weakened bacteria or viruses. The composition of a vaccine
determines the type of immune response created by the body. It is important to note each
category to understand why certain diseases must be vaccinated against in a specific way
due to the natural volatile nature of the bacteria or viruses.

Categories of Vaccines
A vaccine is a manufactured and biological mixture that when injected, provides
protection against a number of diseases in humans. The composition of a vaccine
determines the type of immune response created by the body. There are six categories of
vaccines: live attenuated, inactivated, protein subunit, polysaccharide, polysaccharide
conjugate, and recombinant, that each elicit a different immune response.
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Live Attenuated
Live attenuated vaccines have been available since the 1950s and are derived
from viruses or bacteria that generally cause disease (World Health Organization, 2018c).
With this type of vaccine, the virus enters human cells in a weakened state, replicating
and infecting just enough cells to create an immune response within the body, but not
enough to cause illness of the disease {Feemster, 2018). In live attenuated vaccines, the
immune response created by the body is nearly as good as if the body were to encounter
the disease itself and provides adequate time for the body to produce memory cells. In
extremely rare cases, ranging anywhere from 0.0002%-0.0004% of recipients, the virus
may revert to its pathogenic state, causing severe illness in the recipient. Examples of this
have been seen with vaccine-associated paralytic poliomyelitis, and vaccine-derived
poliovirus related to the oral polio vaccine (World Health Organization, 20 18c). While
this type of vaccine generally creates the closest immune response to natural disease, it is
less safe compared to other categories. Vaccines in this category include the MMR
combined vaccine, smallpox, varicella, rotavirus, and yellow fever (U.S Department of
Health and Human Services, 20 18b).
Inactivated
Inactivated vaccines are made from whole cell viruses or bacteria that have been
killed through chemical or physical processes (World Health Organization, 20 1 8b).
Chemical processes usually use a small amount of formaldehyde to kill yet retain the
composition of the virus or bacteria (Feemster, 20 18). Because the cell is dead, there is
no risk of disease in recipients. However, an immune response may not be induced with a
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single dose potentially requiring several doses throughout the patient's lifespan to
maintain immunity. Vaccines in this category include Hepatitis A, influenza, rabies and
inactivated polio vaccine (IPV) (U.S Department of Health and Human Services, 2018b).

Toxoid
Toxoid vaccines are created with the toxin produced by a certain bacterium that
invades the bloodstream, eliciting an immune response and causing symptoms of disease.
To create the vaccine, the pure toxin is treated with either heat or chemical to attenuate it
(London et al., 2017, p. 1046). To increase the immune response, the toxoid is adsorbed
to calcium or aluminum salts (adjuvants) (World Health Organization, 2018e). One
downfall of the toxoid vaccine is that the vaccine is not as immunogenic as other vaccine
categories, therefore several doses may be needed throughout an individual's lifetime.
However, a toxoid vaccine cannot cause the disease it prevents and is usually long lasting
and more stable than other vaccine categories (World Health Organization, 2018e).
Examples oftoxoid vaccines include tetanus and diphtheria (London et al., 2017, p.
1046).

Subunit
Polysaccharide and polysaccharide conjugate.
Polysaccharide and polysaccbaride conjugate vaccines are used to target bacteria
that are encapsulated by polysaccharides, primarily sugars. The body targets the capsule
first because it is the first material to encounter, so the vaccine does not include the actual
bacteria the body should protect itself from, but the capsule protecting the bacteria inside.
A downside of this technique is that capsule vaccines do not adequately create immune
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memory cells, therefore multiple vaccines but be given over a period. Several bacteria
that can cause severe disease in children are protected against using this technique, such
as Haarophil us i nfl uaizaeb (Hib), pneumococcus, and meningococcus (Feemster,
20 18).
Protein-based.

Protein-based vaccines isolate the antigens of the bacteria that are important to
inducing a protective immune response in the body. The vaccine does not consist of a
whole bacteria or viral cell, therefore to isolate the antigens responsible for inducing
disease, the bacteria must be studied before a vaccine can be created. Because the
bacteria or virus in the vaccine is not live, there is no risk of disease and are much more
stable than live attenuated virus vaccines (World Health Organization, 20 18d). Though
an immune response can be triggered by the vaccine, there is no real guarantee that the
body's memory cells will form correctly. Examples of protein-based vaccines include
acellular pertussis and Hepatitis B (World Health Organization, 2018d).
As new types of vaccines began to be introduced into the healthcare market, there
was an increased need of knowledge of how communicable and infectious diseases were
spread throughout a population. The fathers of immunology, several men who developed
aseptic techniques-who influenced how vaccines are manufactured today.
Manufacturing A Vaccine

To understand how vaccines can prevent the spread of human disease throughout
a population, it is crucial to also understand how the study of immunology and
bacteriology began. Louis Pasteur first introduced the concept that vaccination could
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theoretically be applied to any microbial disease, including prophylactically post
exposure. He also was one of the first scientists to discover that microbes were
responsible for decay of tissues, dairy, beer, wine, and vinegar when introduced to
bacteria (Smith, 20 12}.
Later in Pasteur's career, he shifted from microbiology to the study of
immunology using live attenuated vaccines. He produced a post-exposure prophylactic
rabies vaccine using the live attenuated method, which paved the way for other scientists
to create vaccines using similar methods, such as the live attenuated yellow fever vaccine
in the 1930s (Smith, 2012).
Today, the manufacturing process of vaccines includes many steps to prevent
bacteria and other organisms from growing in the vaccine, as well as keep the vaccine
viable prior to administration. However, when vaccines were first introduced to the
public, there was not as large of a concern. Edward Jenner began by inoculating humans
with bovine cowpox pustules, he did not attempt to attenuate the vaccine, but simply
extracted the fluid from pustules and injected it into humans. While those vaccinated did
not contract smallpox, some had reactions to the vaccine. Many more developed
infections in the injection site and surrounding tissue from lack of proper processing to
remove bacteria from the vaccine (Stem & Markel, 2005). As more vaccines were
developed over the next I 00 years, creating safer vaccines was one of the main concerns.
Creating a new vaccine can range from 5 to 18 years including the research phase
of development (Plotkin et al., 2017, p. 4066}. With each type of vaccine, the
manufacturing process differs in specificity. The antigens of bacteria or viruses are what
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stimulate a human's immune system to create an immune response. Once an antigen is
identified and isolated, it is extracted and concentrated. Attenuation, the process of
weakening the virus or bacteria enough so that the cells may still reproduce to elicit an
immune response, but not elicit the disease in those vaccinated is an important step for a
safe vaccine. Different types of vaccines are manufactured differently, however all must
be attenuated. Once attenuated, preservation and adjuvant ingredients are combined with
the antigenic substance. Once a vaccine is produced, exploratory and pre-clinical trials
begin, followed by human clinical trials with multiple phases. If the results of the clinical
trials show significant efficacy, the vaccine may then be approved and license for
widespread production and use (Plotkin et al., 2017, p. 4069). The completed vaccine is
then put into a vial and packaged or freeze-dried into a powder form for better stability
for transport (Sanofi Pasteur, 20 I 8).
Sanofi Pasteur (2018), a large vaccine production company owned by the Sanofi
pharmaceutical company, outlines their manufacturing process as follows:
l . Bacteria, virus or cell culture: the antigens are developed using raw material.
2. Harvesting: The antigens produced from microorganisms are extracted.
3. Purification: Impurities are removed and concentrated through physical and
chemical processes.
4. Inactivation: Pathogenicity is suppressed while retaining immunological
properties.
5. Valence assembly: The active antigenic substances are combined in a single
component.
6. Formulation: All the ingredients are melted together.
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7. Filling: the vaccine is filled into a vial or syringe.
8. Freeze drying: this step makes it possible to remove the water in a product by
transforming it into powder, which ensures a better stability and therefore a better
conservation.
9. Packaging: The vaccine is labeled in accordance with regulatory requirements
and packed, ready for shipping.
I 0. Batch release: Quality assurance confirms the product has been manufactured
and tested in accordance with the correct procedures. The national regulatory
authority gives the final authorization to release the product for distribution.
1 1. Transport: Our vaccines are distributed all around the world, respecting the
cold chain and a temperature between 2-8°C.
Quality control (QC) tests are completed during each stage of the manufacturing
process. For a batch to be released and distributed, it must pass all stages of QC testing.
Assays include pH and osmolality, antigen stability analyses, excipients and adjuvants,
sterility testing, and concentration and potency tests (Smith, Lipsitch, & Almond, 20 11,
p. 2-3). Depending on the vaccine, additional QC may be warranted. This process may
take weeks, not including additional QC, before batch release for transport (Smith,
Lipsitch, & Almond, 20 1 1 ).
Once a batch of vaccines are released, they are transported using the cold chain, a
series of facilities from manufacturer to end-user to ensure that the batch remains at a
temperature of 2-8°C to maintain product quality (Smith, Lipsitch, & Almond, 20 1 1, p.
4).
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Costs of Vaccines
At each stage of vaccine development, specialized equipment performs certain
tasks in the development process. The more complicated the vaccine is to reproduce, the
more expensive it is. For example, the live attenuated oral polio vaccine is much less
expensive than the pneumococcal conjugate vaccine in terms of lower Cost of Goods
Sold (COGS), or the direct costs related to the production of vaccines sold (Plotkin,
Robinson, Cunningham, Iqbal, & Larsen, 2017, p. 4066). The cost includes both the
materials used and cost of labor to produce the vaccine. One of the main issues plaguing
the vaccine industry over the last 70 years is how to reduce vaccine costs.
A few of the vaccines used today in childhood schedules were developed in the
mid-20'" century. The vaccines' life cycle are maximized by using raw materials and
other supplies that would be available for decades at relatively low cost to developers,
though competition with other industries using the same materials can drive up vaccine
cost (Plotkin et al., 2017, p. 4065).
According to Gerson and Mukherjee (2005), there are three major ways to
minimize vaccine cost: manufacturing at the largest scale practical, use a well understood
and reputable production process, and use the most efficient facilities, equipment, and
machinery to minimize the use of raw energy, personnel, and uncontrolled effects. Major
costs can be attributed to product development (research and development laboratories
and employees), direct labor (employee wages and benefits), and management or IT
systems. Recurring costs such as maintenance and repairs, as well as utilities can make up
between $50-700 million USO depending on facility size (Plotkin et al., 2017, p. 4067).
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Product development remains high, usually greater than $500 million USD (Plotkin et al.,
2017, p. 4067). The United States Department of Defense has estimated that a vaccine
with a 25-year life cycle will ultimately cost 1.56 billion dollars and seven years of time
from start to finish (Plotkin et al., 2017, p. 4069).
Controversial Vaccine Ingredients

When physicians and vaccine developers realized that patients were getting more
ill from bacteria that had grown in the vaccine prior to injection, new ingredients were
added to vaccines to preserve the ingredients and sterilize the vaccine to prevent bacterial
growth. Within the last 20 years, several preservatives and adjuvants used in certain
vaccines, such as the influenza and MMR vaccines, have gained the attention of parents
and caused controversy. Additionally, London et al. (2017) stated that while vaccines are
tested rigorously to ensure safety, serious vaccine reactions may still occur in children. In
1988, The Vaccine Adverse Event Reporting System (VAERS) was created to track
serious vaccine reactions. Should a serious vaccine reaction occur, the National Vaccine
Injury Compensation Program provides compensation for the family (London et al.,
20 17).
Since Andrew Wakefield's publication (Wakefield et al., 1998), stating that the
MMR vaccine may expose children to behavioral regression and pervasive development
disorder, and eventually the diagnosis of Autism, parents have become more vocal about
not vaccinating their children due to multiple concerns regarding the safety and efficacy
of vaccines. While the sample size of the study only consisted of 12 children and only
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included speculated conclusions, it was deemed a success and received plenty of
publicity.
These ingredients, such as aluminum salts and thimerosal, are believed by parents
to cause heavy metal toxicity in the brain and digestive system, inducing a disorder on the
autism spectrum in the child.

Aluminum salts.
In the United States, several vaccines use aluminum salts as an adjuvant to
increase the immune response in an individual after injection, as well as reduce the
number of vaccines needed per antigen for immunity, as well as decrease the amount of
antigen needed in a vaccine reducing possible side effects from the antigen (Fernandez,
2016, p. e23 1). According to the Food and Drug Administration in the United States,
aluminum hydroxide, aluminum phosphate, and potassium aluminum sulfate are licensed
for use in vaccines (U.S Food and Drug Administration, 2018a). Aluminum salts are used
in DTaP, pneumococcal conjugate, tetanus, and hepatitis A and B vaccines. It is known
after over 60 years of research that the levels of aluminum that the body is exposed to
after an aluminum containing vaccine is must less than an individual's normal exposure
to aluminum in food and water supplies, approximately 0.125 to 0.85 mg per dose (U.S
Food and Drug Administration, 201 8a; Fernandez, 20 1 6 p. e231 ). The FDA limits the
amount of aluminum compounds in a vaccine to 0.85- 1 .25 mg per dose (Fernandez,
2016, p. e232). Another study by Principi and Esposito (2018) stated that there is no data
available that show an association between the use of aluminum in vaccines and
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neurotoxicity, though the possible correlation of aluminum adjuvants and macrophagic
myofaciitis should be investigated in the future (Principi & Esposito, 2018, p. 5835).
However, an article was found that compared the data of Autism Spectrum
Disorder (ASD) prevalence from 1991-2008 in the United States and the amount of
aluminum in each vaccine that an infant receives during the first few months of life
(Tomljenovic & Shaw, 20 1 1). The study found a casual correlation between increased
aluminum levels in the body and number of ASD cases related to higher aluminum
adjuvant exposure, however the study did state that correlation does not mean causation,
and that further studies would need to be conducted to confirm the correlation.
Thimerosal.

Thimerosal is an ethylmercury, an organic compound that is 49.55% mercury
(Hg) by weight. First introduced to the medical field in the 1920s, it was a crystalline
powder that quickly replaced the use of Joseph Lister's carbolic acid as antiseptic in
operating rooms. After being patented in 1928 as merthiolate, researchers found that the
patented Hg compound was 40-50 times as effective compared to carbolic acid when
combating 3aphylococcus aureus(Baker, 2008, p. 245). In 1929, physicians gave their
patients merthiolate to treat an epidemic of meningococcal meningitis. While merthiolate
did not get rid of the meningitis, there were no ill effects in the patients from the drug
(Baker, 2008, p. 245).
One of the largest issues facing the growing vaccine industry in the 20'h century
was bacterial contamination of multi-use vaccine vials. In 1916, a batch of typhoid
vaccine became tainted after being stored at room temperature. In all, there were 68
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severe reactions, 26 abscesses, and 4 total deaths (Baker, 2008, p. 245). In 1928, an
incident in Australia occurred with a contaminated batch of diphtheria toxoid, resulting in
12 deaths of the 21 children who received the vaccine due to staphylococcus infections
and toxemia (Baker, 2008, p. 245).
After two cases of bacteria infected vaccines causing disease or death, vaccine
researchers decided that some sort of antibacterial would need to be added to the vaccine
in order to eliminate bacteria that could grow in multidose vials. However, the use of
phenol and cresol in vaccines decreased the effectiveness by reducing the potency of the
products the antiseptics were used to protect against (Baker, 2008, p. 245). When the use
of thimerosal was introduced, it was found to possess the protective properties of phenol
and cresol without reducing the potency (Baker, 2008).
As thimerosal became one of the main antiseptics used in childhood vaccines into
the 1930s and 1940s, the question arose from parents regarding the concern of mercury
poisoning. It was important to educate parents in that organic mercury is a
methylmercury, usually found in fish and air pollution, and was different than thimerosal,
an ethylmercury. Thimerosal dissociates into ethyl-mercury chloride, ethyl-mercury
hydroxide, and sodium thiosalicylate in saline, therefore it is believed it reacts similar in
the human body (Gier et al., 2015).
In the late 1990s and early 2000s, further concerns from parents arose with the
popularity of Andrew Wakefield's study regarding the possible correlation with autism
and other neurotoxicity disorders. Though the FDA and other researchers conducted
several studies, each study concluded that there was little to no risk of neurotoxic
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disorders or generalized toxicity concerns. However, the FDA decided to remove the use
of thimerosal from all common childhood vaccines by 2001 to remove the possibility of
reactions or side effects in children U.S (Center for Disease Control and Prevention,
2015e). Today, common vaccines that still contain thimerosal include multidose
influenza trivalent and quadrivalent vaccines, single strain influenza, and tetanus
diphtheria (not to be confused with Tdap) (U.S Food and Drug Administration, 20 18b).
An Overview of Vaccination Policies
Regulations regarding vaccinations throughout the world help shape policies for each
country and state to best protect their citizens from communicable diseases. Due to the
dangerous and potentially deadly nature of the diseases mentioned previously, several
government organizations have set guidelines and policies for childhood vaccines that
work to decrease the incidences of preventable disease and death in children.
Global Vaccination Policies
Global vaccination policies are outlined by the World Health Organization
(WHO) and the WHO Strategic Advisory Group of Experts (SAGE). The SAGE
committee meets biannually to review the currently vaccination recommendations. The
committee also regularly updates position papers on vaccinations of communicable
diseases that pose an international public health impact and are used in large scale
vaccination programs. These papers are updated when new information and scientific
evidence emerges regarding the disease and potential vaccination changes (Duclos &
Okwo-Bele, 2007). In the position papers, SAGE outlines the major clinical
manifestations of the disease and at-risk groups. Vaccinations that are available to the
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public for each specific disease are also mentioned, including the type of vaccination
(often there is more than one option for each disease), which age group it is available to,
when during the lifespan the vaccination should be administered, and contraindications.
It is important to recognize that developing countries also must work to devote
more funding into healthcare and increased vaccination percentages to reduce the risk of
infectious disease outbreaks that could tum into an epidemic. Funding appears to be the
main setback in developing countries being unable to increase vaccination rates among
their general population, with isolated communities being the second. If citizens are
difficult to reach due to geography, the chance of those citizens being vaccinated, even
for the five vaccinations that are available due to mass funding from the WHO and other
government agencies are slim (Duclos & Okwo-Bele, 2007).
In 1974, the WHO launched the Expanded Program on Vaccination (EPI). The
program helped namely developing countries by providing guidelines on how to
implement and access essential vaccinations. Focusing on infants and pregnant women,
the initial phase attempted to vaccinate these populations with bacilli Clamette-Guerin
(BCG} for tuberculosis (which is no longer mandated for administration due to issues
with vaccine efficacy), measles, pertussis, diphtheria, tetanus, and poliomyelitis (Duclos
& Okwo-Bele, 2007). Because of this initiative, by the 1 990s, over 70% of the global
population was considered effectively vaccinated (Duclos & Okwo-Bele, 2007}. As an
example, since the implementation of the EPI the mortality rate of measles has fallen by
60% worldwide since 1999, which exceeded the goal of 50% between 1999 and 2005 set
by the United Nations (Duclos & Okwo-Bele, 2007).
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As of 20 1 1, many of the vaccinations that are regularly administered in developed
countries, examples including Influenza, Haarophi I us i nfl uenzae type b, Rubella, and
Hepatitis, are underused in developing countries. Developing countries do not have clear
disease surveillance and reporting systems, making it difficult for government agencies to
understand the potential impact of certain communicable diseases, as well as risk versus
benefit when investing in additional vaccinations for citizens. (Duclos & Okwo-Bele,
2007). Therefore, most developing countries continue to only vaccinate for the original
five vaccinations that were launched in 1974.
United States of America Vaccination Policies
The United States has a strict schedule for vaccination administration that is
carefully chosen by the CDC with recommendations from the WHO. Within the CDC,
there is the Advisory Committee on Vaccination Practices (ACIP) that chooses the
recommended vaccination schedules for children, adolescents, and older adults based on
scientific evidence from internal studies and from the WHO. The ACIP shares their
vaccination schedule recommendations with the CDC, who then mandates the schedule
for the general population of the United States.
Birth to age 18 requirements.

From birth to age 2, children are given up to 30 vaccinations. School-age and
daycare requirements are namely used as "safety nets" for the children that are either not
old enough to receive the vaccination (MMR or MMRV, for example), or are behind on
their vaccination schedule (National Conference of Legislatures, 20 15). While the ACIP
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and CDC mandate and recommend a safe vaccination schedule, it is ultimately up to each
state's legislation to decide which vaccinations should be mandated for administration.
The recommended vaccination schedule for children and adolescents aged 18 or
younger is updated each year. It is approved by the Advisory Committee on Vaccination
Practices, the American Academy of Pediatrics, the American Academy of Family
Physicians, and the American College of Obstetricians and Gynecologists (U.S
Department of Health and Human Services, 20 18a). The current schedule recommends
30 vaccinations, not including yearly influenza vaccinations (Appendix A). For some
vaccinations, additional doses may be administered if the child is considered high risk for
contracting the disease.
Federal Programming
Funding.

Childhood vaccinations are costly to the country. Recommended vaccinations
until the age of 18 costs $ 1,105 for male populations, and $ 1 ,407 for females as of 2008
for one child. In contrast, the recommended vaccinations in 1 985 cost $45 per child. It is
believed that inflation and the introduction of new vaccinations have boosted vaccination
costs (National Conference of Legislatures, 20 15).
In the United States, there are two main sources of federal funding for vaccination
programs. The Vaccines for Children Program (VFC) provides free vaccinations for
children who are without insurance, are underinsured, eligible for Medicaid, Native
American, or an Alaska Native. According to the National Conference of State
Legislators (2015), the National Vaccination Program within the CDC donated
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approximately $2.5 billion in funds to state and local public health centers for vaccination
purchases, all in the VFC's name. Section 3 1 7 of the Public Health Services act is a
program that provides grants to states and cities for vaccination purchase, as well as
public health programs including disease surveillance. Under the Affordable Care Act
(ACA), the program can now also purchase recommended vaccinations for adults as well
as children. These two programs account for approximately 95% of all publicly funded
vaccinations (National Conference of Legislatures, 2015).

State of Michigan Vaccination Policies
School requirement laws are stated based, chosen by recommendation of ACIP.
However, there are several vaccinations that are required to be administered by the time a
child reaches certain ages to attend daycare or school in the state. The child must meet
the criteria by the time they enter kindergarten, and again once the child begins seventh
grade or are 7-1 8 years old (Appendix B).
The state ofMichigan does not mandate any other vaccinations to allow children
to attend school, but still follows the recommendation of the United States' policy
regarding vaccinations. Should the child attend child care or preschools before the age of
5, there are additional mandated vaccinations that the child must have to attend before
certain age milestones. The state of Michigan also has a PDF file that clearly outlines the
specifics of when each vaccination should be administered. In addition to the
vaccinations the child must have to attend kindergarten and seventh grade if the child also
attends child care or preschools they must also show immunity to pneumococcal
conjugate (PCV1 3) and H. influaizae type b (Hib). Four total doses of PCV13 must be
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administered before the child is four years old, and three doses of Hib must be
administered at or 1 5 months (Michigan Department of Health and Human Services,
2017a).
Should the child attend school, they must either be vaccinated, or the family must
submit documentation of vaccine exemption, which allows the child to remain
unvaccinated yet still attend school.

Provider and Parent Communication
With many families recently becoming more adamant on not allowing their
children to be vaccinated, an increase in preventable diseases have been recognized. The
single most important factor when interacting with parents who do not wish to vaccinate
their children is to ask the parents what specifically is keeping their children from getting
vaccinated. It is now up to the provider to provide proper and effective education to
parents regarding their concerns and possible misconceptions of vaccine injury, safety,
and effectiveness.
Adequate communication between patients, parents, and providers ensures that
everyone understands the risks and benefits involved when approaching vaccination and
disease. One of the first and most famous incidences of miscommunication regarding the
spread of disease and later vaccination, was that of Mary Mallon, also known as Typhoid
Mary.
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Mary Mallon
Mary was an Irish-American immigrant who worked for wealthy families as a
cook beginning in 1906. She was one considered a "healthy carrier", a subject who
contracted the disease but did not show symptoms. While working as a cook, Mary
unknowingly infected upwards of three thousand people in Manhattan, New York.
George Sober, a sanitary engineer, began to investigate the new typhoid outbreak in
Manhattan and traced it back to Mary Mallon. He followed her for many months to
obtain blood and stool samples from Mary, who refused each time. Mary continued to
work in kitchens around New York City for months, even though she knew she would
infect countless other citizens (Marineli, Tsoucalas, Karamanou, & Androutsos, 2013).
Mary did not seem to understand the severity ofthe disease she was spreading to
thousands of people, and no doctor ever attempted to describe how serious typhoid fever
was to her. Symptoms of typhoid fever included fever, headache, nausea, constipation or
diarrhea, loss of appetite, and rash. If left untreated, the disease could progress to
intestinal bleeding and perforation, causing severe abdominal pain, nausea, vomiting, and
sepsis. Other complications included myocarditis, endocarditis, pneumonia,
hepatosplenomegaly, meningitis, and delirium (The College of Physicians of
Philadelphia, 2018f). The progressed symptoms of disease are what killed thousands
prior to the discovery of the typhoid vaccine.
A vaccine for typhoid fever would not be developed until 1 9 1 1, nor any antibiotic
treatment made available until 1948. Therefore, it was crucial for Mary to be removed
from the public to prevent her from continuing the spread of disease. Sober enlisted the
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help of Dr. Biggs, who worked for the New York Department of Health, and the local
police department to bring in Mary for testing. She attempted to run from the police for
over five hours, but in the end was captured and forced to give a stool sample, which
returned positive for typhoid. She was then taken to Riverside Hospital on North Brother
Island for quarantine (Marineli et al, 2013).
Mary was held on North Brother Island for nearly two years. In that time, not one
doctor attempted to explain the importance of Mary's carrier diagnosis or how to
properly avoid the spread of the disease. Instead, they offered multiple times to remove
her gallbladder, and treated her multiple times with laxatives and yeast (Marineli et al,
20 13}.
Mary was freed from captivity after vowing to never work with food or as a cook
again, though she never kept the promise. She continued work under a new name, Mary
Brown, and infected a minimum of 25 people before she was placed back on North
Brother Island until her death in 1938. An autopsy revealed the Mary shed the disease
from gallstones in her gallbladder, which rose the question of whether Mary would have
continued to infect individuals had she accepted the operation when first proposed so
many years ago (Marineli et al, 20 13}.
By officials and physicians electing to punish Mary for the outbreaks she caused,
they left out the most important facet to patient care, communication. Had Mary been
properly educated on the spread of disease and how to prevent it, perhaps she could have
stopped the infection of several thousand people, as well as the death of hundreds. Since
the Typhoid Mary incident, and many other situations like it, healthcare providers have
realized that patient education is important in maintaining high rates of vaccination.

44

INCREASING COMMUNICATION THROUGH IMPROVED NURSING
EDUCATION
However, there are still many shortcomings when attempting to educate parents on
vaccinating their children.
Continued Shortcomings of Vaccine Education
With many parents electing to not vaccinate their children under the pretenses of
nonmedical or religious exemption, in December of 2014 the Michigan Department of
Health and Human Services, along with the Joint Committee on Administrative Rules,
approved a new educational requirement for parents who decide to opt their children out
of vaccinations before starting kindergarten (Michigan Department of Health and Human
Services, 2018). The education is through each county's health department and includes
outlining the benefits ofvaccination and the risk of disease for children who are not
vaccinated. A health educator with the local health department must also be present to
answer any questions or concerns parents may have about vaccines (Michigan
Department of Health and Human Services, 20 18).
One weakness that the 20 I 4 program faces, as well as nearly every health care
setting in the United States, is the lack of appropriate literacy levels for parents. A study
by Davis et al. (2004) stated that on average, most American adults read at or below a
sixth-grade reading level, though vaccine information statement (VIS) pamphlets made
available for parents by the CDC at vaccination appointments or through the health
department's education classes are typically written at around a ninth-grade reading level.
This means that adults reading at a lower level are only comprehending less than half of
each VIS provided for vaccine education. When parents attend vaccine exemption
education classes, they are given information that they cannot process. Therefore, it is
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almost impossible for parents to ask questions to soothe their concerns regarding
childhood vaccinations if they do not understand what they are reading.
In the healthcare setting, provider education is another shortcoming. Nurses
reported spending much more time discussing vaccines and addressing parents' questions
compared to pediatricians or physicians (Davis et al., 2001). Public health nurses reported
that they believed they were doing a good job communicating with families regarding
how the child handled their previous vaccinations, educating parents on the vaccinations
their children would receive during their visit, discussing potential side effects and
treatment options, and stressing the importance of returning for subsequent vaccinations.
However, the nurses stated they avoided discussing risks of vaccinations with families, as
they felt unskilled and undereducated in the topic and were unsure of how to facilitate the
conversation with families (Davis et al., 2004). Instead, the topic was avoided, and
parents left with their concerns and questions unanswered, and potentially left without
vaccinating their children (Davis et al., 2004).
Parental Concerns

When vaccine preventable diseases were still prevalent in the general American
population, the decision for parents to vaccinate their children was almost automatic.
With vaccination and herd immunity rates beginning to drop, today's vaccine hesitant
parents may not remember or know how severe vaccine preventable diseases may be
(Glanz, Kraus, & Daley, 2015). According to London et al. (2017) some parents today
believe that vaccine-preventable diseases are no longer a danger to children because they
occur in the popular so infrequently.
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High vaccination rates are needed to protect vulnerable populations via herd
immunity, such as those who cannot receive vaccinations due to medical complications,
children who have vaccine failure and whose body does not respond to vaccinations, and
those who are simply too young to be vaccinated (Glanz et al., 20 15).
Advocates for vaccines have typically used information from "pro-vaccine"
sources, such as government agencies, local health departments, and pharmaceutical
companies. However, vaccine hesitant parents have been shown in recent studies to be
untrusting of such evidence due to potential sponsorships or incentives given for
disseminating the information to the public, for example, "kick-backs" the sponsoring
companies may receive (Glanz et al., 201 5). In another recent study, the use of evidence
based information from agencies such as the CDC to educate vaccine hesitant parents
decreased parents' intention to vaccinate (Nyhan, Reifler, Richey, & Freed, 20 1 4).
A survey of parents found that they preferred one-on-one conversations about
information regarding their child's vaccinations. Topics parents wanted to be educated
about included vaccine side effects, treatment of side effects, and the date of their child's
next vaccines (Davis et al., 2004). Focus groups held for parents reported that many
parents were never educated on potential severe side effects from vaccines and believed
that they should have been informed as a matter of respect from the physician or nurse
(Davis et al., 2004). However, parents may have felt that they could not ask the questions
they wanted to be educated on due to appointment time constraints. Davis et al., (2004)
stated that as of 2004, immunization visits lasted for an average of 20 minutes from start
to finish. Communication between parents and providers regarding the risks and benefits
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of the vaccines the child would receive that day lasted for an average of 16 seconds.
Between written materials for parents created at too high of a literary level and allowing
an average of 16 seconds for concerns to be discussed (Davis et al., 2004), it is no wonder
that parents have increasingly decided to not vaccinate their children and continue to
have unresolved concerns regarding vaccination.
In a 2010 survey that was completed by 4,198 families, only 23% (964) of parents
stated that they had no concerns regarding their child's vaccinations (Kennedy, Basket, &
Sheedy, 2011). Another study revealed that parents' greatest concerns regarding vaccines
include the increasing number of vaccines administered at each visit, ingredients in
vaccines, and the increasing media attention of controversies including vaccines, namely
that vaccines may cause autism (Kennedy, LaVail, Nowak, Basket, & Landry, 2011).
Research by Glanz et al., (2014) shows that vaccine hesitant parents have a high
regard for their providers but are skeptical of their provider's education of vaccines.
Parents report that physicians and nurses are more likely to discuss the positive effects
vaccinations have rather than a more balanced view, also highlighting the possible
negative side effects or severe side effects vaccines may have on their children. It appears
that parents want providers to explicitly and frankly state the rare but real several adverse
effects that can occur when vaccinating a child. Parents believe that a provider
acknowledging the risks parents are concerned about can facilitate a sense of trust on a
higher level (Glanz et al., 2014). They are looking for unbiased trustworthy sources of
information regarding the safety and potential risks of vaccines, and their providers
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simply handing then a leaflet from the CDC is not going to cut it anymore (Glanz et al.,
2014).

Current Education Practices
A systematic review completed by Connors, Slotwinski, and Hodges (20 1 7)
outlined nine studies regarding current communication practices by healthcare providers
throughout the world regarding vaccination. In the United States, it was reported that a
fear-based education regarding vaccinating against preventable communicable disease
was used most often. Another study mentioned in Connors et al., (20 1 7), stated that 44%
of family practice physicians and 53% of pediatricians attempted to soothe parental
concerns by advising the parents it was more painful for the child to receive their
vaccinations throughout multiple office visits as opposed to receiving all at once. Fewer
physicians also reported feeling confident about answering the more difficult questions of
adverse reactions (Connors et al., 2017).
In a Canadian study by Busse, Walji, and Wilson (201 1), physicians were
considered biased by clients due to only providing positive or incomplete vaccine
information when parents expressed concern. Parents requested unbiased resources
regarding vaccine safety, and 1 7.3% of parents reported that discussing vaccine choices
and concerns created a conflict between the provider and parent. A study by Connors et
al., (201 7) reported that the literature referenced above supported involving vaccine
hesitant families in their child's care; most often through participation and using a more
individualized plan of care to ease parental concerns and answer potential questions.
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Providers reported many barriers to vaccine discussion with parents, such as the
length of time discussions took, the precedence of other health issues, providers believing
that the discussion would not be likely to change parents' minds of vaccinating their child
on schedule, providers reporting they did not know enough regarding the evidence of
vaccine safety, or believing that parents would not understand the information given to
them regarding risks and benefits (Kempe et al., 20 1 1). Many providers also reported not
knowing how to communicate with parents the risks of vaccines (Kempe et al., 201 1 ).
Pediatric or public health nurses are often responsible for facilitating difficult
conversations with parents regarding vaccination, as they are usually the provider
administering vaccines to children. Davis et al. (2004) stated that nurses may be less apt
to give detailed education regarding vaccines because there is a lack of national policy
regarding vaccine communication that specifically outline vaccine risks and benefits.
While many risks are in the vaccine information statements (VIS) given to parents at
vaccination office visits, nurses should not rely on the VIS alone to provide such
sensitive information to parents. Because of the lack of policy, nurses are often left
wondering how they can help to increase vaccination rates to prevent outbreaks of
preventable disease.
Nursing and Improving Vaccination Rates

As nurses, it is our job to be the patient's advocate. In terms of vaccination, the
nurse's goal should be to provide unbiased evidence-based information to the family to
make an educated decision on vaccinating their child, as well as ensuring children are
fully vaccinated. Improving communication between parents and providers should also
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be a priority, with the concerns of parents mentioned previously in the forefront of the
mind. Parents want to protect their children and do what they believe will be best for
them. Without proper education, parents may unknowingly harm their child by
preventing them from being vaccinated. There are many ways that nurses can facilitate
and improve communication with parents without passing judgement or blame onto the
parents.
Prior to any education with parents, nurses must self-evaluate their own position
on vaccination. Regardless of whether a nurse may be for or against vaccines, they must
be educated in all aspects, including administration, side effects, safety, efficacy, and
education. Taking the time to self-educate will make having conversations with parents
who have difficult questions much easier, as the nurse will be educated appropriately
using evidence-based practice.
Increasing the time for education opportunity is an important improvement that
should be made in the healthcare setting. Such a small amount of time spent, especially
with vaccine hesitant parents, is not long enough to fully vaccinate a child while ensuring
parents are properly educated on all aspects of vaccination. It is a nurse's position to
facilitate a conversation with parents, particularly with parents who do not seem to have
any questions about vaccination, as parents tend to only ask questions about vaccines
27% of the time at their child's vaccine appointments (Davis et al., 2004). Using the
teach-back method for parents such as these may prove to be helpful, especially to gauge
how much of the discussion was retained {Fredrickson, Davis, & Bocchini, 2001).
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Mentioned previously, nurses spent an average of 16 seconds educating parents
on the potential for risks and severe reactions, amounting to less than 3% of total visit
time (Davis et al., 2004). Davis et al.'s (2004) study followed nurses at several different
physician's offices and found that in more than 90% of the observed visits, nurses did
discuss common side effects of vaccines and how to treat them at home. Benefits of
vaccination were discussed 48% of the time, whereas only 28% of the time were severe
risks and how to take care of a child discussed. In approximately 13% of visits, severe
reactions such as a fever over 105°F or seizures were mentioned.
In addition to increasing conversation time and encouraging parents to ask
questions, providers and nurses reported a few strategies that could be more helpful in
educating vaccine resistant parents. Ideas included adjusting information to concerns
voiced by the parent or the parent's background, providing information for the vaccine
their child would receive at their next visit prior to the appointment, and providing a
screening tool for a parent to fill out prior to the appointment to help identify specific
parental concerns if they are evident (McRee, Gilkey, & Dempsey, 20 14). Another study
stated that parents who received education information regarding their child's
vaccinations at the time of the visit did not give them enough time to process the
information and ask questions (Glanz et al., 20 15). By providing information and
screening tools prior to a vaccination visit, providers could better individualize a plan of
care for the family and address parental concerns more adequately (McRee, Gilkey, &
Dempsey, 2014).
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London et al. (2017) lists several additional ways that nurses can ensure that
children are fully vaccinated and reduce the number of missed opportunities for
vaccination:
1. Place a reminder in the child's health record to alert health professionals about
the child's need for immunizations. Establish a system to send parents a
reminder when the child's immunizations are due or overdue.
2. Give vaccines when the child has a minor illness, even with a low-grade fever
and antibiotic treatment, or has a recent exposure to an infectious disease.
3. Use combination vaccines (e.g, DTaP-HepB-IBV) to reduce the number of
injections from 20 to 13 in the first 2 years oflife.
4. Give multiple vaccines at the same time using separate syringes and injecting
in separate sites. If using the same extremity, separate injection sites by an
inch.
5. Give medically stable low-birth-weight infants all vaccines appropriate for
chronologic age as full-term infants. Use the full dose.
6. Give the vaccine even when a prior dose caused a local reaction or a family
member had an adverse response.
It is the nurse's position to prevent increased morbidity and mortality of
individuals in relation to preventable disease via vaccination. If nurses and physicians are
willing to take the time to sit down with parents and attempt to truly understand parents'
concerns regarding vaccination, parents will leave feeling more trusting of their
providers, and feel that the nurse or physician's best interest is in the wellbeing of the
child. With increase trust and education, parents are more likely to vaccinate their
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children on time, increasing herd immunity and protecting children who are unable to be
vaccinated from preventable disease.
Educating parents on the history of now preventable disease and why vaccinating
is so important is the first step in increased communication. Concerns regarding the
safety of vaccines can be educated on by sharing the manufacturing process and rigorous
quality control testing that each dose of vaccine must go through, as well as mentioning
controversial ingredients and explaining why the ingredients may not be harmful for
children after all. Vaccine policy may also be mentioned, particularly when and why
children get the vaccines they are scheduled for at specific intervals. To communicate
these topics with parents effectively and without bias, strategies mentioned above should
be used to ease parental concerns. Through increased communication with families,
vaccination rates should increase, protecting children from preventable disease and
potential lifelong disability or death.
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Appendix A
Recommended Vaccine Schedule for Children Aged O to 18 Years in The Unite

::zu.

FlgYre 1. R4commended lmmunlution SCheduM ffff' Cldldr.n •nd Adoleaa-n\s �gect 1■ Y'••n. orVaul\g...-Unltad S&a1-. 201,..
IFOR THOSl!WHO FAU. IIOilND 011 START I.Ant. HI? nu, CATCH.UP $CHEDUL.£ [FIGUIIE
� tccommcnd.atklns mu.st t. tcad with thlt foothot.c1 that folSOw. fol' tho�c who ra11 Mhlnd or n•n latec;;eide Qtc.h--tlp vacdn.lktn &t the e,arUen opportun
To d•••rmlrw minimum intervals be1wwen dO'M"I. ... tM catc.h--up KNtdute (J\fture :ZJ, School entry •nd ad esc.nit v.ac�lne av• groups •r• �ded '" gray,
11>-ll
,�,o
IMcdne
Blnh
1 ma
4moa
,a..2•1yn

._.......

··-

(_

.............,!RIil RVI P•--IIY51l__,
Dphdwrie.talanla.•�a.r
�• CCT•P: c7 yn)

H--iypeb'
!Hibl
Pnaumaaacail canjugatel
CKV'l31
ll'WCl:IYilted polio'ltlftu1•

(lP'Y:<1ern)

,_(IV)
Mcula.mums:a.n.1be0.a' tMMR)
V•- (VMI

::z..-

!'I--

·2"'-

........

..

······••daiiii

t•�

--

....

Z""diiiii
2"'-

::z-diii
2""-

.,,_

�.
:r:r-

:r--'�-

i..

-�-�

Manlnc,oax.cal11 o,41.b-MenCY

"6-�-D � mo1:
M«'l'\AC'W'Y"°""' a�mON

..

..-d-

..

..

---·

◄--

..

·--

..

1•diiiiir

;;

"i

Alwlual wcdfloftlon OIV1 1 Cll'2doMI- ,-.

,._

..

-�-......,Sii-1a ----

.s-e,...,....,..,,

T�dtohtheft.&.&Kdlua.,J"'f'U,lfod1,•.t(Tdap2;7 �

HunWln

papa�--

......

fia-1:..�=:-..--

f,,

HePldttt. A 1 (HepA)
0

........

.,..,.,.

-:r-

CHPV)

I

....,...

I

s•-

I

I

I
I

I ••- 1 J
l
2""clioe
�

I

J

.
I

□

M.,.il"ICJOCOCUI 111 I
Pnoumocuu..1-ldc'
IPPSVXI)

I

N0T£:The above recommendation• must ba read along wlU. tha footnotes of this schedule.

For further infonnation on the recommended vaccine schedule and a catch-up schedule, see
https://www.cdc.Rov/vaccines/schedules/hcp/imz/child-adolescent.html
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Appendix B
Vaccines Required for School Entry (2017)

DTP, DTaP, Tdap

Kindergarteners 4-6 years

7th graders or children 7-18

old

years old

4 doses DTP or DTaP, 1

1 dose Tdap at 1 1 years old

dose at or after 4 years old

prior to entry into 7,h grade

Polio (IPV)

4 doses or 3 total doses if dose 3 was given after 4 years old

MMR

2 doses after 12 months of age {or documented immunity)

Hepatitis B

3 doses (or documented immunity)

Meningococcal conjugate

NIA

1 dose at 1 1 years old prior to
entry into 7th grade

Varicella

2 doses after 12 months of age, lab immunity, or history of
disease

Number of vaccine doses per child needed to attend schools in Michigan for full
immunity.
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